Home | Welcome to Contract Pharma   
Last Updated Thursday, April 17 2014
Print

BIND, Amgen Amend Accurin Drug Pact



By Kristin Brooks



Published December 13, 2013
Related Searches: Preclinical Development
BIND Therapeutics has amended its development and commercialization collaboration with Amgen to extend Amgen’s exercise option by six months. The global collaboration entails the development and commercialization of a kinase inhibitor nanomedicine to treat a range of solid tumors based on BIND’s Accurin platform for targeted and programmable nanomedicines and Amgen’s undisclosed proprietary kinase inhibitor.
 
Amgen’s option period to select a novel Accurin candidate for further development has been extended to July 7, 2014 to allow for completion of the research plan. Both companies are working on preclinical development and Amgen will assume responsibility for any future development and commercialization. BIND is eligible to receive upfront and development milestone payments totaling $46.5 million, and an additional $134 million in regulatory and sales milestones, as well as royalties on future sales.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On